Standout Papers

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma 2017 2026 2020 2023 2.3k
  1. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma (2017)
    Joaquim Bellmunt, Ronald de Wit et al. New England Journal of Medicine

Immediate Impact

3 by Nobel laureates 20 from Science/Nature 64 standout
Sub-graph 1 of 22

Citing Papers

Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
Y chromosome loss in cancer drives growth by evasion of adaptive immunity
2023 StandoutNature
6 intermediate papers

Works of Yabing Mai being referenced

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout

Author Peers

Author Last Decade Papers Cites
Yabing Mai 1798 1534 289 517 19 2.6k
Suba Krishnan 1723 1222 431 443 21 2.6k
Alexandre Lambert 1785 991 363 691 27 2.5k
Lora Weiselberg 804 1371 314 668 33 2.4k
Lisa Sengeløv 1414 2085 564 1033 45 3.4k
Christian Poehlein 2606 1585 537 1112 77 3.7k
C.J. van Groeningen 1072 996 509 583 49 2.3k
Keith E. Volmar 1703 662 614 503 45 2.3k
Thomas Papadopoulos 813 1098 534 573 58 2.3k
Aristotle Bamias 1845 832 769 769 86 3.2k
T. Oliver 1161 2752 559 640 16 3.3k

All Works

Loading papers...

Rankless by CCL
2026